ValiRx continues “advanced conversations” with possible partners for VAL401 lung cancer drug

04:13 EDT 14 Jun 2018 | Proactive Investors

ValiRx released the positive results of a phase II trial of its lead drug earlier this year and it is now looking for a partner to help take VAL401 through a phase III study and into the market

More From BioPortfolio on "ValiRx continues “advanced conversations” with possible partners for VAL401 lung cancer drug"